Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma
Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma
复制标题
DOI：
10.1111/j.1476-5829.2009.00199.x
复制
发表时间：
2010-03-01
影响因子：
2.1
通讯作者：
Post, G. S.
中科院分区：
文献类型：
--
作者：
Daters, A. T.;Mauldin, G. E.;Post, G. S.
本研究的目的是评价在含有环磷酰胺、阿霉素、长春新碱、L-天冬酰胺酶和强的松方案的基础上加用米托蒽醌的疗效。对65只患有多中心淋巴瘤的狗进行了总体缓解和生存时间的评估。观察缓解期和生存期与分期、亚期、治疗前高钙血症和治疗前激素应用的关系。患有多中心淋巴瘤的狗的总体中位缓解时间为302天，总的中位生存期为622天。在患有多中心淋巴瘤的狗中，23只(35%)接受了所有预定剂量的米托蒽醌。仅中位生存期与亚期有显著差异(a亚期中位生存期为679d，b亚期中位生存期为302d，P=0.025)。与历史对照相比，增加阿霉素和米托蒽醌的联合总剂量可能会改善缓解时间，需要进一步研究以确定如何在犬多中心淋巴瘤的多药化疗方案中最好地利用米托蒽醌。
The purpose of this study was to evaluate the efficacy of adding mitoxantrone to a cyclophosphamide, doxorubicin, vincristine, l-asparaginase and prednisone containing protocol. Sixty-five dogs with multicentric lymphoma were evaluated for overall remission and survival times. Remission and survival time versus stage, substage, pretreatment hypercalcaemia and pretreatment steroid administration were also evaluated. Overall median remission for dogs with multicentric lymphoma was 302 days and overall median survival was 622 days. Of the dogs with multicentric lymphoma, 23 (35%) received all scheduled mitoxantrone doses. Only median survival versus substage was found to be significant (substage a median survival was 679 days and substage b median survival was 302 days, P = 0.025). Increasing the total combined dose of doxorubicin and mitoxantrone may improve remission times when compared with historical controls, and further studies are needed to determine how best to utilize mitoxantrone in multidrug chemotherapy protocols for canine multicentric lymphoma.